Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699638 | 1.00 | CYP3A4 (0.59) | CYP3A4NPC1CLK1RAB9AMAPK14 | |
| SCHEMBL15153847 | 0.94 | CYP3A4 (0.67) | CYP3A4MAPK14 | |
| SCHEMBL1699492 | 0.94 | CYP3A4 (0.67) | CYP3A4MAPK14 | |
| SCHEMBL15153916 | 0.94 | CYP3A4 (0.67) | CYP3A4MAPK14 | |
| SCHEMBL15165226 | 0.94 | CYP3A4 (0.60) | CYP3A4MAPK14 | |
| SCHEMBL10271706 | 0.92 | CYP3A4 (0.58) | CYP3A4NPC1CLK1RAB9AMAPK14 | |
| SCHEMBL10271704 | 0.92 | CYP3A4 (0.58) | CYP3A4NPC1CLK1RAB9A | |
| SCHEMBL10272109 | 0.92 | CYP3A4 (0.58) | CYP3A4NPC1CLK1RAB9A | |
| SCHEMBL10272104 | 0.92 | CYP3A4 (0.58) | CYP3A4MAPK14 | |
| SCHEMBL15165304 | 0.91 | CYP3A4 (0.57) | CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | CYP3A4 2058/4885NPC1 19/4885CLK1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.